Premium
The influence of the Pro12Ala mutation of the PPAR‐gamma receptor gene on metabolic and clinical characteristics in treatment‐naïve patients with type 2 diabetes
Author(s) -
Ahluwalia M.,
Evans M.,
Morris K.,
Currie C.,
Davies S.,
Rees A.,
Thomas A.
Publication year - 2002
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1046/j.1463-1326.2002.00230.x
Subject(s) - medicine , endocrinology , insulin resistance , type 2 diabetes , triglyceride , peroxisome proliferator activated receptor , obesity , adipocyte , cholesterol , diabetes mellitus , receptor , biology , adipose tissue
Peroxisome proliferator activated receptor‐gamma is an important factor in adipocyte differentiation and energy metabolism and is thus a candidate gene for obesity, insulin resistance and dyslipidaemia. We therefore assessed the associations between the most common variant of the PPAR‐γ, the Pro12Ala (P12A) substitution in the PPAR‐γ 2 gene, with BMI, blood pressure, fasting plasma glucose, HbA 1c , total cholesterol, LDL and HDL cholesterol and plasma triglyceride in 183 treatment‐naïve patients with type 2 diabetes (T2D). The P12A allele associated with lower fasting plasma glucose but had no influence on HbA 1c or BMI. In obese patients (BMI > 29 kg/m 2 ), the P12A substitution associated with elevated total and non‐HDL cholesterol levels.